Hanmi Pharm has announced its intention to aggressively pursue large-scale CMO (Contract Manufacturing Organization) and CDMO (Contract Development Manufacturing) projects.
Hanmi Pharmaceutical announced today that it will participate in the "2023 BIO-Europe Spring Conference" to be held in Basel, Switzerland from March 20 to 22 and hold business meetings with a number of global pharmaceutical companies.
BIO-Europe Spring is an event where global pharmaceutical and bio companies and related investors build networks and promote partnerships.
Through individual business meetings for each company, Hanmi Pharmaceutical is actively promoting the Pyeongtaek Bio Plant's high-tech large-scale manufacturing facilities (up to 12,500 liters incubator) optimized for commercial production of biopharmaceuticals, and specialized personnel and systems that can operate them. We plan to carry out order-taking activities.
Hanmi Pharm's Pyeongtaek bio plant currently has a production capacity that can manufacture more than 20 million prefilled syringes per year based on finished drugs.
In particular, the Bio Plant Plant 2, which was completed in 2018, has a separate space where facilities can be flexibly expanded according to CMO demand, so it can flexibly respond to large-scale CMO orders from global pharmaceutical companies.
Unlike major domestic CMO companies equipped with animal cell culture-based facilities, the Pyeongtaek Bio Plant has manufacturing facilities using microbial culture, which makes it possible to mass-produce biopharmaceuticals made in this way quickly and economically.
In addition, DNA and mRNA vaccines, which are newly attracting attention after the corona pandemic, can be manufactured on a large scale. Based on the R&D capabilities accumulated over a long period of time, we can provide end-to-end services that include manufacturing of raw materials and finished drugs, quality testing, and preparation of approval data.
“We plan to expand the CMO business more actively based on the capacity for mass production and quality control of biopharmaceuticals confirmed through Rollbedon’s entry into the US market,” said Kim Se-kwon, director of Hanmi Pharm (Bio Manufacturing Development Team). We will make company-wide efforts to build it into a new growth engine.”
